Loncar China BioPharma ETF
Compare this stock
CHNA Stock Report Card
$
23%
Performance
Score:
10/100
CHNA returned -3.63% in the last 12 months. Based on SPY's performance of 12.05%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
11/100
CHNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Volatility
Score:
60/100
CHNA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.
Loncar China BioPharma ETF Summary
Nasdaq / CHNA
The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
CHNA scored poorly on our reportcard. Here are some similar companies and how they performed.
